News Focus
News Focus
Followers 269
Posts 18897
Boards Moderated 0
Alias Born 01/19/2006

Re: biopharm post# 327944

Friday, 08/10/2018 2:51:58 AM

Friday, August 10, 2018 2:51:58 AM

Post# of 347009
BTW, TPIV was + ~13% yesterday, closing at $8.23

https://investorshub.advfn.com/TapImmune-Inc-TPIV-1454/

Remember a former PPHM CEO is there.

John Bonfiglio, Ph.D MBA
President & COO

John is a highly successful Biotech CEO with broad experience in corporate strategy and financing, market interactions and business development. He was most recently President and CEO of Oragenics where he refocused the company and raised over $29 million dollars in the public markets while positioning the company for a successful re-listing on the NYSE: MKT stock exchange. He was formerly President and CEO of Argos Therapeutics where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million) and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation’s Immunotherapy Division. John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y